-
Mashup Score: 0Individualized Maintenance Niraparib Dosing Confers Favorable OS in Recurrent Ovarian Cancer - 1 year(s) ago
The use of an individualized starting dose of niraparib led to a trend toward improved overall survival as maintenance therapy vs placebo in Chinese patients with platinum-sensitive, recurrent ovarian cancer regardless of germline BRCA mutation status, according to data from the phase 3 NORA trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Individualized Maintenance Niraparib Dosing Confers Favorable OS in Recurrent Ovarian Cancer - 1 year(s) ago
The use of an individualized starting dose of niraparib led to a trend toward improved overall survival as maintenance therapy vs placebo in Chinese patients with platinum-sensitive, recurrent ovarian cancer regardless of germline BRCA mutation status, according to data from the phase 3 NORA trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The use of an individualized starting dose of #niraparib led to a trend toward improved OS as maintenance therapy vs placebo in Chinese patients w/ platinum-sensitive, recurrent ovarian cancer regardless of germline BRCA mutation status. #ovca #oncology https://t.co/14UJ1jx2Di https://t.co/3ZzgWS6gV6
-
-
Mashup Score: 0
Significant PFS results demonstrated in NORA trial don’t extend to overall survival
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
For women with platinum-sensitive recurrent #ovariancancer, maintenance therapy using an individualized starting dose of #niraparib (#Zejula) did not improve OS despite producing a statistically and clinically significant PFS benefit. https://t.co/LSC9b2jnH3 #OncTwitter
-
-
Mashup Score: 0Niraparib and Radium-223 for mCRPC: Phase 1 Study Results - 1 year(s) ago
Further study is needed to determine if certain biomarkers can aid in determining the effectiveness and safety of combining PARP inhibitors with other agents.
Source: GU Oncology NowCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A new treatment combination that includes the PARP inhibitor #niraparib and radium-223 may be effective for patients with metastatic castration-resistant #prostatecancer. Read more: https://t.co/1IV2YKMSNw https://t.co/9VSdzF3uDY
-
-
Mashup Score: 0
The primary endpoint of 6-month progression-free survival was met in the niraparib plus ipilimumab maintenance group, whereas niraparib plus nivolumab yielded inferior progression-free survival. These findings highlight the potential for non-cytotoxic maintenance therapies in patients with advanced pancreatic cancer.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Also in our August issue: #Niraparib plus #nivolumab or niraparib plus #ipilimumab in patients with platinum-sensitive advanced #pancreaticcancer: a randomised, phase 1b/2 trial https://t.co/HBci82F8zp
-
-
Mashup Score: 0
During a Targeted Oncology case-based roundtable event, Matthew Powell, MD, discussed trials supporting the use of the PARP inhibitors niraparib and olaparib for patients with BRCA-positive ovarian cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
During a Targeted Oncology case-based roundtable event, Matthew Powell, MD, discussed trials supporting the use of the PARP inhibitors #niraparib and #olaparib for patients with BRCA-positive #OvarianCancer. #oncology #gynsm https://t.co/yKLACLiES9
-
-
Mashup Score: 3
Niraparib is tolerable and shows anti-tumour activity in heavily pretreated patients with metastatic castration-resistant prostate cancer and DRDs, particularly in those with BRCA alterations.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ICYMI – now in the March issue: GALAHAD - #niraparib in patients with metastatic castration-resistant #prostatecancer and DNA repair gene defects: a multicentre, open-label, phase 2 trial https://t.co/x2j3UuTg0w #pcsm #PARPinhibitor
-
-
Mashup Score: 0NICE recommends the PARP inhibitor niraparib for ovarian cancer treatment via the NHS - 2 year(s) ago
A PARP inhibitor, niraparib, has been endorsed for routine use in the NHS by NICE to treat some forms of ovarian cancer.
Source: Oncology CentralCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A PARP inhibitor called #niraparib has been endorsed for routine use in the NHS by @NICEComms to treat some forms of ovarian, peritoneal or fallopian tube cancer. https://t.co/E8JNxudFt0
-
-
Mashup Score: 1
The combo of the PARP inhibitor niraparib and the multikinase inhibitor cabozantinib showed positive early efficacy and safety signals in patients with metastatic urothelial carcinoma or renal cell carcinoma.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Patients with bladder and kidney cancers benefit from niraparib/cabozantinib combo, data suggests https://t.co/p5ALaI0EZT #Niraparib #Cabozantinib #KidneyCancer #BladderCancer #Urology #Urologist
-
-
Mashup Score: 0
Findings from the phase 3 MAGNITUDE trial showed that adding niraparib to abiraterone acetate significantly extended radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Niraparib plus abiraterone delays mCRPC progression, study finds https://t.co/sZbVB3VAdI #Niraparib #Abiraterone #ProstateCancer #Urology #Urologist #GU22
-
The use of an individualized starting dose of #niraparib led to a trend toward improved OS as maintenance therapy vs placebo in Chinese patients w/ platinum-sensitive, recurrent ovarian cancer regardless of germline BRCA mutation status. #ovca #oncology https://t.co/AUut5w6kfu